Merck Breaks Ground on $3 Billion Pharmaceutical Manufacturing Center in Virginia
Introduction:
Merck has started construction on a $3 billion Centre of Excellence for Pharmaceutical Manufacturing in Elkton, Virginia. The 400,000-square-foot facility is part of Merck’s long-term plan to expand domestic manufacturing and research capacity, strengthening the U.S. position in global biopharmaceutical innovation.
Features:
The new centre builds on nearly 85 years of Merck’s presence in Elkton and will feature state-of-the-art production and testing for both Active Pharmaceutical Ingredients (API) and Drug Products.
The project is expected to create more than 500 permanent jobs and around 8,000 construction roles, supporting economic growth in the region.
This investment is part of a wider $70 billion programme beginning in 2025 to advance research, manufacturing, and supply capabilities across the country.
Recent U.S. projects include new facilities in North Carolina, Delaware, Kansas, and New Jersey, collectively adding thousands of jobs and improving vaccine and medicine production capacity.
Merck’s expansion underlines its continued commitment to innovation and its goal of ensuring reliable, high-quality pharmaceutical production within the United States.
The Elkton facility is scheduled for completion in 2029.
Specifications:
| Name | Merck |
| Budget | $3 Billion |
| Type | Construction |
| Year of Completion | 2029 |
